Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

医学 伊立替康 吉西他滨 胰腺癌 内科学 肿瘤科 危险系数 胃肠病学 生物标志物 化疗 结直肠癌 癌症 生物 置信区间 生物化学
作者
Valeria Merz,Camilla Zecchetto,Raffaela Santoro,Francesca Simionato,Fabio Sabbadini,Domenico Mangiameli,Geny Piro,Alessandro Cavaliere,Michela Deiana,Maria Teresa Valenti,Diana Bazan,Vita Fedele,Sara Lonardi,Davide Melisi
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (17): 4661-4669 被引量:22
标识
DOI:10.1158/1078-0432.ccr-20-0395
摘要

Abstract Purpose: Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI) is a novel treatment for metastatic gemcitabine-refractory pancreatic cancer. We endeavored to identify circulating markers for TAK1 activation predicting chemoresistance in this setting. Experimental Design: In vivo activity of nal-IRI was validated in an orthotopic nude murine model expressing TAK1-specific shRNA. Plasma concentration of 20 different cytokines were measured by a multiplex xMAP/Luminex technology in patients prospectively enrolled to receive nal-IRI plus 5-fluorouracil/leucovorin (5-FU/LV). The optimal cutoff thresholds able to significantly predict patients' outcome were obtained on the basis of the maximization of the Youden's statistics. Results: Differential expression profiling revealed the gene coding for IL8 as the most significantly downregulated in shTAK1 pancreatic cancer cell lines. Mice bearing shTAK1 tumors had significantly lower plasma levels of IL8 and experienced a significant reduction in tumor growth if treated with nal-IRI, whereas those bearing TAK1-proficient tumors were resistant to this agent. In a discovery cohort of 77 patients, IL8 was the circulating factor most significantly correlated with survival (plasma levels lower vs higher than cutoff: mPFS 3.4 months vs 2.8 months; hazard ratio [HR], 2.55; 95% CI, 1.39–4.67; P = 0.0017; median overall survival 8.9 months vs 5.3 months; HR, 3.51; 95% CI, 0.84–6.68; P = 4.9e−05). These results were confirmed in a validation cohort of 50 patients. Conclusions: Our study identified IL8 as the most significant circulating factor for TAK1 pathway activation and candidates IL8 as a potential predictive biomarker of resistance to nal-IRI in gemcitabine-refractory patients with pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
地表飞猪应助科研通管家采纳,获得10
刚刚
科研通AI2S应助科研通管家采纳,获得10
刚刚
传奇3应助科研通管家采纳,获得10
刚刚
情怀应助科研通管家采纳,获得10
刚刚
英俊的铭应助科研通管家采纳,获得10
刚刚
YamDaamCaa应助科研通管家采纳,获得30
刚刚
刚刚
orixero应助科研通管家采纳,获得10
刚刚
大个应助科研通管家采纳,获得10
刚刚
SciGPT应助科研通管家采纳,获得10
刚刚
1秒前
所所应助过氧化氢采纳,获得10
3秒前
青山发布了新的文献求助50
4秒前
4秒前
大白发布了新的文献求助10
4秒前
4秒前
热情的达完成签到,获得积分10
4秒前
酷波er应助十九岁的时差采纳,获得10
4秒前
gj发布了新的文献求助10
5秒前
Hairee发布了新的文献求助10
5秒前
momo发布了新的文献求助10
9秒前
称心尔曼完成签到,获得积分10
10秒前
12秒前
14秒前
谷蓝完成签到,获得积分10
14秒前
16秒前
希望天下0贩的0应助Hairee采纳,获得10
17秒前
Rondab应助ali采纳,获得30
18秒前
懒羊羊完成签到,获得积分10
18秒前
好吃完成签到,获得积分20
18秒前
好吃发布了新的文献求助10
21秒前
21秒前
22秒前
23秒前
量子星尘发布了新的文献求助10
23秒前
张雯思发布了新的文献求助10
23秒前
fjm完成签到,获得积分10
23秒前
老实雁蓉完成签到,获得积分10
24秒前
fjm发布了新的文献求助10
25秒前
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158